Abstract
With respect to new reproductive technologies, in the United State the private sector is given a comparatively free rein, whereas with regard to the application of biogenetic technology, what appears to be a laissez-faire situation in the United States is in actuality a set of decentralized policies. These policies, expressed primarily through judicial decisions, have set precedents that, because of the lack of a federal policy, constitute contradictory and ad hoc rulings which for the most part are detrimental to indigent populations. The absence of a comprehensive national public health program in the United States similar to the French one necessarily works against those who cannot afford private medical care, and with the continued development of medically-assisted procreation and the application of biogenetic research, this reality will be intensified.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
